AOD-9604 is a 16-amino-acid synthetic fragment of human growth hormone (residues 177-191), studied for its lipolytic activity without the diabetogenic effects of full-length HGH.
AOD-9604 is a 16-amino-acid synthetic fragment of human growth hormone (residues 177-191), studied for its lipolytic activity without the diabetogenic effects of full-length HGH. Mechanism: HGH fragment (177-191). Typical route: Subcutaneous injection. FDA status: Not FDA-approved as a finished drug product. The FDA reviewed AOD-9604 as a food ingredient in 2014 (GRAS notice) but has not approved it as a therapeutic peptide. Some peptide compounding pharmacies
Drug classHGH fragment (177-191)
Half-life~30 minutes
RouteSubcutaneous injection
Research dosing250-300 mcg/day
FDA statusNot approved
Available throughCompounding pharmacies (varies)
Mechanism of action
AOD-9604 is hypothesized to mimic the lipolytic C-terminal domain of human growth hormone, stimulating triglyceride breakdown and inhibiting lipogenesis while sparing growth hormone's glucose-affecting receptor activities. Clinical evidence is limited; large RCTs have not confirmed meaningful weight loss in humans.
Dosing reference
Research dosing protocols in literature use 250-300 mcg subcutaneously once daily, typically taken in the morning on an empty stomach. AOD-9604 is not FDA-approved for any indication; dosing information is included for reference, not endorsement.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
Not FDA-approved as a finished drug product. The FDA reviewed AOD-9604 as a food ingredient in 2014 (GRAS notice) but has not approved it as a therapeutic peptide. Some peptide compounding pharmacies dispense it under research-chemical or compounded-formula frameworks.
Editor's Pick · #1 of 10
NexLife — Semaglutide Program
Editor's PickPhysician-led503A pharmacyAll 50 states
Physician-led telehealth platform with Dr. Adam Kennah as Medical Director. Compounded semaglutide from an FDA-registered 503A pharmacy, all-inclusive pricing covering medication, supplies, and prescriber visits.
Trade-offs to know: Compounded medication, not FDA-approved Wegovy or Ozempic. Cash-pay only — not billable to insurance. Async telehealth model (no live video by default).
Editor's Pick · #1 of 10
NexLife — Tirzepatide Program
Editor's PickPhysician-led503A pharmacyAll 50 states
Physician-led tirzepatide program with the same compounding pharmacy, prescriber team, and clinical protocols as the semaglutide program. Methylcobalamin combined formulations available.
Trade-offs to know: Compounded medication, not FDA-approved Zepbound or Mounjaro. Cash-pay only. Tirzepatide is a newer compound with a shorter real-world safety record than semaglutide.
Large, well-controlled randomized trials have not shown clinically meaningful weight loss with AOD-9604 in humans. Marketing claims often exceed the evidence base. GLP-1 agonists like semaglutide and tirzepatide have substantially stronger evidence for weight loss.
Is AOD-9604 worth using instead of semaglutide?
Based on the current evidence base, no. GLP-1 receptor agonists have substantially stronger trial evidence and FDA approval for weight management. AOD-9604 may be of academic interest but should not be considered an evidence-based weight-loss therapy.
SS
Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
AS
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
JE
Edited by
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.